HD Biosciences Funded by Lilly, Pfizer and Morningside

HD Biosciences Inc., a biology-focused contract research organization (CRO) based in Shanghai, formally announced the closing of its Series A financing. The first announcement had come at the ChinaBio® Investor Forum held July 7-8 in the Park.  The round was led by Morningside Venture with Lilly Asian Ventures and Pfizer Venture Investments joining.  HDB's funding may well be the first example of multiple big pharma's taking an equity position in a China-based CRO.  HD Biosciences is a specialized CRO focused on conducting assay development and high throughput screening services for big pharma and biotech.  More details... Stock Symbol:  (NYSE: LLY) (NYSE: PFE) (HSI: HWL)